Paper published in Nature Communications
Thursday, May 15, 2025
A paper co-authored by Director Keisuke Goda and Representative Director Takashi Nitta, entitled "Direct evaluation of antiplatelet therapy in coronary artery disease by comprehensive image-based profiling of circulating platelets," has been published in the online version of the scientific journal Nature Communications.
In this paper, circulating platelet aggregates in the blood of 207 patients with coronary artery disease were captured on a large scale using high-speed fluid imaging with a microfluidic chip, and image analysis was performed using AI to directly evaluate platelet function. The results showed that compared to healthy subjects, patients with coronary artery disease had increased platelet aggregation and platelet aggregation was suppressed depending on the number of antiplatelet drugs administered, and that this was observed equally in both venous and arterial sites. These results are expected to contribute to the screening of patients with coronary artery disease, as well as the individualization, optimization, and non-invasive monitoring of antiplatelet therapy.
As an expert in cell analysis, CYBO will continue to contribute to the development of the industry.
The paper “Direct evaluation of antiplatelet therapy in coronary artery disease by comprehensive image-based profiling of circulating platelets" co-authored by Keisuke Goda and Nao Nitta has been published in the online edition of the scientific journal Nature Communications.
In this paper, circulating platelet aggregates in blood samples from 207 coronary artery disease (CAD) patients were imaged on a large scale by high-speed flow-imaging using a microfluidic chip, and the images were analyzed using AI to evaluate platelet function directly. The results showed that platelet aggregation was enhanced in patients with coronary artery disease compared to healthy subjects, and that platelet aggregation was suppressed in response to the number of antiplatelet agents, and these findings were replicated in both venous and arterial sites. With these results, this technology is expected to contribute to screening of patients with CAD, personalization and optimization of antiplatelet therapy, and non-invasive monitoring.
As experts in cellular analysis, we will continue to contribute to the advancement of the industry.
